Supriya Ganesh Swaps Medical School for Medical Drama
By James Moreau | 28 Feb, 2026
Following a Golden Globe award, The Pitt and star Supriya Ganesh are now the frontrunners for an ensemble win at the Actor Awards.
In her first series regular role, actor Supriya Ganesh stars as Dr. Samira Mohan in the current HBO Max medical drama The Pitt. She has starred in all 30 episodes of the Emmy Award winning show’s 2 seasons. Prediction markets currently favor the series to win Outstanding Performance by an Ensemble in a Drama Series at the 2026 Actor Awards.
Prior to being cast in the hit show, Ganesh had built a television resume full of guest appearances on Law & Order: SVU, Grown-ish, and Billions. Her screen debut came in 2018 on an episode of CBS’s Blue Bloods.
The 28-year-old followed an unconventional path to Hollywood. Born in the United States to Tamil parents she spent much of her childhood in New Delhi after moving there at three years old. She was involved in theater but also was a high achiever who graduated high school as valedictorian.
She scored in the 99th percentile on her MCAT exam and moved back to the U.S. to pursue neuroscience at Columbia University. After arriving in New York Ganesh quickly picked up an agent following a series of early auditions.
With The Pitt already renewed for a third season, Ganesh remains a breakout talent to watch during awards season and for future starring roles.
Recent Articles
- S. Korea Exports Seen Rising Sharply Again in April on Chip Boom
- House Democrats Urge Trump to Keep Ban on Chinese Cars
- China Tech Firms Scramble for Huawei AI Chips after DeepSeek V4 Launch
- US Orders Halt on Chip Equipment Shipments to China's No. 2 Chipmaker
- Spot Crude Premiums Ease Despite Hormuz Closure
- Trump Approval Sinks to New Low on Living-Cost Jump from Iran Adventure
- LG Electronics, Nvidia Mull Pact on Robots, AI data Centrer and Mobility
- Starbucks Shares Rise on Signs of Turnaround
- Robinhood Shares Fall as Crypto Slump Dents Trading Volume Growth
- Mercedes Profit Tumbled on China Sales Slump, Tariff Pressures

